Skip Navigation


European Heart Journal Advance Access originally published online on April 24, 2007
European Heart Journal 2007 28(9):1043-1044; doi:10.1093/eurheartj/ehm083
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
28/9/1043    most recent
ehm083v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bagwe, S.
Right arrow Articles by Mehta, J. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bagwe, S.
Right arrow Articles by Mehta, J. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2007. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

High-risk acute coronary syndrome patient and cardiac biomarkers in the emergency department: where do we stand?

Suveer Bagwe, Rajesh Sachdeva and Jawahar L. Mehta*

Division of Cardiovascular Medicine, University of Arkansas for Medical Sciences and the Central Arkansas Veterans Healthcare System, Little Rock, AR 77205-7199, USA

* Corresponding author. Tel: +1 501 296 1401; fax: +1 501 686 6180. E-mail address: mehtajl@uams.edu

This editorial refers to ‘Treatment and outcomes of patients with evolving myocardial infarction: experiences from the SYNERGY trial’{dagger} by C.D. Miller et al., on page 1079

The first 10% of the full text of this article appears below.

Each year, more than five million patients are seen in emergency department (ED) for evaluation of symptoms of myocardial ischaemia. The use of cardiac markers is a standard practice to risk-stratify these patients. The interaction between duration of symptoms, timing of testing, and clearance kinetics of biomarkers determines whether a marker will be positive. Current guidelines of the ACC/ESC recommend serial measurements of CK-MB and/or cardiac troponins.

Cardiac troponins are regulatory proteins with cytosolic and structural pools. They are released upon myocardial necrosis. Troponin levels at admission provide much needed information for the evaluation and prognostication of patients who present with myocardial necrosis.1,2 . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Treatment and outcomes of patients with evolving myocardial infarction: experiences from the SYNERGY trial
Chadwick D. Miller, Anindita Banerjee, Kenneth W. Mahaffey, Michael C. Kontos, Gregory Fermann, Charles V. Pollack, Jr., Elliott Antman, Philip Aylward, Shaun G. Goodman, Renato Santos, James J. Ferguson, Robert M. Califf, and James W. Hoekstra
EHJ 2007 28: 1079-1084. [Abstract] [FREE Full Text]  



This article has been cited by other articles:


Home page
 Eur Heart JHome page
D. Roy and J. C. Kaski
High-risk acute coronary syndrome patients and cardiac biomarkers in the emergency department: any role for new biomarkers of myocardial ischaemia?
Eur. Heart J., September 2, 2007; 28(18): 2297 - 2297.
[Full Text] [PDF]